Cancer drug lifts British Biotech
Friday 01 December 1995
British Biotech saw its stock market value soar pounds 244m to pounds 748m yesterday after the fledgling biotechnology company reported what could be a breakthrough for its new anti-cancer drug, marimastat.
The new oral drug was shown to halt the growth or actually reduce cancerous tumours in a third of the 94 patients involved in the initial human test programme. The rate of increase in tumours was slowed in a further 26 per cent.
The news prompted the shares to jump pounds 5.05 to pounds 15.48 yesterday, with excited City analysts suggesting that they could hit pounds 20 next year.
Dr Peter Lewis, British Biotech's head of research and investment, said: "This is the first evidence from human trials that marimastat may have an effect on the progression of human cancer." However, he said firm conclusions must await completion of clinical testing.
Phase III trials could start in the second half of next year, with analysts pencilling in approval of the drug in Europe and the US by 1999. The latest results make it virtually certain that holders of British Biotech warrants will now convert into ordinary shares in December and January, raising pounds 47.5m for the company and ensuring its continued survival.
British Biotech announced a pounds 4.03m loss for the three months to October, taking the deficit in the latest half year to pounds 11m from pounds 12.3m before.
- 1 Game of Thrones season 6: Jon Snow theorists believe Ned Stark's son may have a twin sister
- 2 Artist takes LSD, draws herself over different stages of the 9-hour trip to show its effects
- 3 Miley Cyrus address Robin Thicke VMA controversy: ‘He wanted me as naked as possible, but I got the heat because I’m a woman’
- 4 iPhone 6s camera: features to include 4K video camera and flash for selfies
- 5 A pint of water every day is the key to losing weight, scientists say
Miley Cyrus address Robin Thicke VMA controversy: ‘He wanted me as naked as possible, but I got the heat because I’m a woman’
Most expensive city to live in for expatriates: Luanda, Angola takes number one spot with Hong Kong and Zurich in top three
Irish tourist filmed fighting with shopkeepers in Turkey says they 'messed with the wrong man'
House of Lords: Outcry as donors, fixers and MPs caught up in expenses scandal get peerages
Moody neurotics are more likely to be creative geniuses, study says
Dresden riots: Protesters in Germany attack refugee buses shouting 'foreigners out'
France train shooting: US soldiers speak of the moment they stopped gunman and 'beat him until he was unconscious'
Labour leadership: Jeremy Corbyn accused of 'deluding' young supporters with 'claptrap'
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith 'should resign over disability benefit death figures', says Jeremy Corbyn
iJobs Money & Business
£25000 - £30000 per annum: Recruitment Genius: From modest beginnings the comp...
£35000 - £40000 per annum: Recruitment Genius: From modest beginnings the comp...
£15000 - £65000 per annum: Recruitment Genius: This is an exciting opportunity...
£18000 - £20000 per annum: Recruitment Genius: This is a fantastic opportunity...